PMC:7074432 / 7382-8396 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"254","span":{"begin":45,"end":54},"obj":"Species"},{"id":"255","span":{"begin":138,"end":147},"obj":"Species"},{"id":"258","span":{"begin":161,"end":170},"obj":"Chemical"},{"id":"259","span":{"begin":172,"end":181},"obj":"Chemical"},{"id":"260","span":{"begin":183,"end":190},"obj":"Chemical"}],"attributes":[{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"Tax:2697049"},{"id":"A255","pred":"tao:has_database_id","subj":"255","obj":"Tax:2697049"},{"id":"A258","pred":"tao:has_database_id","subj":"258","obj":"MESH:D061466"},{"id":"A259","pred":"tao:has_database_id","subj":"259","obj":"MESH:D019438"},{"id":"A260","pred":"tao:has_database_id","subj":"260","obj":"MESH:C086979"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T268","span":{"begin":45,"end":54},"obj":"SP_7"},{"id":"T267","span":{"begin":85,"end":101},"obj":"CHEBI:22587;CHEBI:22587"},{"id":"T266","span":{"begin":138,"end":147},"obj":"SP_7"},{"id":"T265","span":{"begin":161,"end":170},"obj":"DG_23"},{"id":"T264","span":{"begin":172,"end":181},"obj":"DG_30"},{"id":"T263","span":{"begin":183,"end":190},"obj":"CHEBI:57472;CHEBI:57472;DG_49"},{"id":"T262","span":{"begin":196,"end":207},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T261","span":{"begin":218,"end":229},"obj":"CHEBI:465284;CHEBI:465284"},{"id":"T260","span":{"begin":277,"end":283},"obj":"CHEBI:38867;CHEBI:38867"},{"id":"T259","span":{"begin":299,"end":314},"obj":"CHEBI:50858;CHEBI:50858"},{"id":"T258","span":{"begin":331,"end":345},"obj":"GO:0019814"},{"id":"T257","span":{"begin":778,"end":786},"obj":"SP_7"},{"id":"T256","span":{"begin":823,"end":828},"obj":"GO:0016265"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T14","span":{"begin":331,"end":345},"obj":"Body_part"},{"id":"T15","span":{"begin":517,"end":524},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A15","pred":"fma_id","subj":"T15","obj":"http://purl.org/sig/ont/fma/fma85272"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":517,"end":524},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0003893"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T38","span":{"begin":778,"end":796},"obj":"Disease"},{"id":"T39","span":{"begin":787,"end":796},"obj":"Disease"}],"attributes":[{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":526,"end":527},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T33","span":{"begin":580,"end":583},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T34","span":{"begin":686,"end":687},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T35","span":{"begin":798,"end":800},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T74","span":{"begin":85,"end":101},"obj":"Chemical"},{"id":"T75","span":{"begin":161,"end":170},"obj":"Chemical"},{"id":"T76","span":{"begin":172,"end":181},"obj":"Chemical"},{"id":"T77","span":{"begin":183,"end":190},"obj":"Chemical"},{"id":"T78","span":{"begin":196,"end":207},"obj":"Chemical"},{"id":"T79","span":{"begin":218,"end":229},"obj":"Chemical"},{"id":"T80","span":{"begin":241,"end":257},"obj":"Chemical"},{"id":"T81","span":{"begin":299,"end":314},"obj":"Chemical"},{"id":"T82","span":{"begin":548,"end":556},"obj":"Chemical"},{"id":"T83","span":{"begin":704,"end":719},"obj":"Chemical"},{"id":"T84","span":{"begin":854,"end":859},"obj":"Chemical"},{"id":"T85","span":{"begin":945,"end":950},"obj":"Chemical"}],"attributes":[{"id":"A74","pred":"chebi_id","subj":"T74","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A75","pred":"chebi_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A76","pred":"chebi_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A77","pred":"chebi_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A78","pred":"chebi_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_465284"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_50846"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_50858"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"LitCovid-sentences","denotations":[{"id":"T44","span":{"begin":0,"end":80},"obj":"Sentence"},{"id":"T45","span":{"begin":81,"end":1014},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}

{"project":"2_test","denotations":[{"id":"32201439-31986264-47219427","span":{"begin":209,"end":211},"obj":"31986264"},{"id":"32201439-32007143-47219428","span":{"begin":231,"end":233},"obj":"32007143"},{"id":"32201439-31986264-47219429","span":{"begin":316,"end":318},"obj":"31986264"},{"id":"32201439-32007143-47219430","span":{"begin":913,"end":915},"obj":"32007143"},{"id":"T85215","span":{"begin":209,"end":211},"obj":"31986264"},{"id":"T15501","span":{"begin":231,"end":233},"obj":"32007143"},{"id":"T97145","span":{"begin":316,"end":318},"obj":"31986264"},{"id":"T54773","span":{"begin":913,"end":915},"obj":"32007143"}],"text":"The details of treatment reported in case of 2019-nCoV are presented in Table 1. The antiviral agents which are used in the management of 2019-nCoV episodes are lopinavir, ritonavir, arbidol,[28] oseltamivir,[12] i.v. ganciclovir.[29] Among immunomodulators, the commonly used agents are systematic corticosteroids,[1230] and i.v. immunoglobulin was used in more serious cases who were refractory to initial therapy.[28] Among herbal medicines, Chinese herbal medicinal products Tanreqing i.v. gtt,[31] shufeng jiedu capsule (a traditional Chinese medicine) was used.[28] The WHO has specified that at this present time there is no high level evidence is available, which favous use of a single specific antiviral agent for the treatment of patients with suspected or confirmed 2019nCoV infection.[27] Although many of the death cases were in higher age group[32] and many were smokers and had bilateral disease,[29] lack of appropriate control group is the main hindrance in interpreting these prognostic factors."}